JP7430136B2 - 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 - Google Patents

疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 Download PDF

Info

Publication number
JP7430136B2
JP7430136B2 JP2020523389A JP2020523389A JP7430136B2 JP 7430136 B2 JP7430136 B2 JP 7430136B2 JP 2020523389 A JP2020523389 A JP 2020523389A JP 2020523389 A JP2020523389 A JP 2020523389A JP 7430136 B2 JP7430136 B2 JP 7430136B2
Authority
JP
Japan
Prior art keywords
cells
disease
cell
markers
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501318A (ja
JP2021501318A5 (enExample
Inventor
イー． ジョン ウェリィ
バートラム ベングシュ
オマール カーン
ジェニファー ウー
ジョゼフィン ジャイルズ
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2021501318A publication Critical patent/JP2021501318A/ja
Publication of JP2021501318A5 publication Critical patent/JP2021501318A5/ja
Application granted granted Critical
Publication of JP7430136B2 publication Critical patent/JP7430136B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020523389A 2017-10-27 2018-10-26 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 Active JP7430136B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762578193P 2017-10-27 2017-10-27
US201762578212P 2017-10-27 2017-10-27
US62/578,212 2017-10-27
US62/578,193 2017-10-27
US201862660754P 2018-04-20 2018-04-20
US62/660,754 2018-04-20
US201862661467P 2018-04-23 2018-04-23
US62/661,467 2018-04-23
PCT/US2018/057850 WO2019084493A1 (en) 2017-10-27 2018-10-26 METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SUSPECTED T CELLS

Publications (3)

Publication Number Publication Date
JP2021501318A JP2021501318A (ja) 2021-01-14
JP2021501318A5 JP2021501318A5 (enExample) 2021-12-09
JP7430136B2 true JP7430136B2 (ja) 2024-02-09

Family

ID=66246753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523389A Active JP7430136B2 (ja) 2017-10-27 2018-10-26 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物

Country Status (4)

Country Link
US (2) US11906511B2 (enExample)
EP (1) EP3701041A4 (enExample)
JP (1) JP7430136B2 (enExample)
WO (1) WO2019084493A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1083956S1 (en) * 2018-12-10 2025-07-15 Icahn School Of Medicine At Mount Sinai Display screen with a graphical user interface
WO2020246846A1 (ko) * 2019-06-05 2020-12-10 연세대학교 산학협력단 Tox에 기초한 면역 항암 요법에 대한 치료 반응 예측 방법
WO2021006316A1 (ja) * 2019-07-10 2021-01-14 国立研究開発法人国立がん研究センター がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー
EP4055180A4 (en) * 2019-11-05 2023-12-06 Cofactor Genomics, Inc. METHODS AND SYSTEMS FOR PROCESSING COMPLEX DATA SETS USING ARTIFICIAL INTELLIGENCE AND DECONVOLUTION
CN111154835A (zh) * 2020-01-19 2020-05-15 广州基迪奥生物科技有限公司 一种ATAC-seq测序文库的构建方法
EP4133059A4 (en) * 2020-04-07 2024-10-02 University Health Network COMPOSITIONS AND METHODS FOR INCREASING CD8+ T CELL ACTIVATION AND CYTOLYTIC ACTIVITY BY DISRUPTION OF THE SAGA (SPT-ADA-GCN5-ACETYLTRANSFERASE) COMPLEX
CN115768879A (zh) 2020-04-28 2023-03-07 莱尔免疫制药公司 用于培养细胞的方法
CN111748627A (zh) * 2020-07-02 2020-10-09 北京化工大学 膀胱癌耗竭型t细胞亚群、其特征基因及其应用
CA3193687A1 (en) * 2020-09-23 2022-03-31 The Trustees Of Columbia University Metabolic augmentation to promote and enhance immune response by tcf1+ t cell repopulation
CN112501292B (zh) * 2020-11-09 2022-12-02 中国人民解放军海军军医大学 cFAM210A在制备肝癌诊断或术后预测试剂盒以及药物中的应用
EP4301773A4 (en) * 2021-03-03 2025-06-25 The Board of Trustees of the Leland Stanford Junior University POLYPEPTIDE CONSTRUCTS WITH NOVEL BINDING AFFINITY AND USES THEREOF
WO2023023269A1 (en) * 2021-08-20 2023-02-23 The Board Of Trustees Of The Leland Stanford Junior University Identification of pathogenic immune cell subsets in checkpoint inhibitor-induced myocarditis
WO2023034530A1 (en) * 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
WO2023060071A1 (en) * 2021-10-04 2023-04-13 H. Lee Moffitt Cancer Center And Research Institute Inc. Dna methylation signatures for predicting response to immunotherapy
CN118251487A (zh) * 2021-10-26 2024-06-25 巴黎-萨克雷大学 源自高功能性自体干细胞的t细胞免疫疗法
JP2023064788A (ja) * 2021-10-27 2023-05-12 国立大学法人京都大学 Ｔ細胞の評価方法及びｔ細胞評価用の組成物
CN115040538A (zh) * 2022-05-23 2022-09-13 重庆医科大学 人cxcr5＋cd8＋t细胞在制备治疗慢性乙型肝炎的药物中的应用
CN114752628B (zh) * 2022-05-30 2023-06-30 四川大学华西医院 C57bl/6小鼠多发性骨髓瘤模型的构建方法及应用
CN115029429B (zh) * 2022-06-02 2022-11-22 中国人民解放军总医院第五医学中心 炎症相关蛋白联合在预测art治疗敏感性中的应用
CN115040663B (zh) * 2022-06-15 2023-12-12 上海交通大学医学院附属仁济医院 溶质载体家族38成员2在制备多发性骨髓瘤治疗药物中的应用
CN115058504B (zh) * 2022-07-14 2025-07-04 广州医科大学 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用
WO2024074713A1 (en) * 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
WO2024097677A1 (en) * 2022-11-01 2024-05-10 BioLegend, Inc. Analyzing per-cell co-expression of cellular constituents
CN119700985A (zh) * 2023-09-22 2025-03-28 清华大学 Bcor和Zc3h12a在预防和治疗慢性感染中的用途
CN117017991A (zh) * 2023-09-26 2023-11-10 中山大学附属第三医院 Hdac6选择性抑制剂在制备慢性乙型病毒性肝炎抗病毒治疗药物中的应用
CN118818055A (zh) * 2024-06-05 2024-10-22 复旦大学附属华山医院 用于筛选胶质瘤dc疫苗潜在受益人群的试剂盒及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500730A (ja) 2007-10-26 2011-01-06 ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント Ｔｉｍ−３を用いた治療および診断方法
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017165412A2 (en) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061456A2 (en) 2014-10-17 2016-04-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500730A (ja) 2007-10-26 2011-01-06 ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント Ｔｉｍ−３を用いた治療および診断方法
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017165412A2 (en) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAITSCH, L. et al.，Exhaustion of tumor-specific CD8+T cells in metastases from melanoma patients，The Journal of Clinical Investigation，2011年05月09日，Vol.121, No.6，pp.2350-2360
WHERRY, E. J. et al.，Molecular signature of CD8+ T cell exhaustion during chronic viral infection，Immunity，2007年10月18日，Vol.27, No.4，pp.670-684

Also Published As

Publication number Publication date
EP3701041A1 (en) 2020-09-02
EP3701041A4 (en) 2021-11-17
US20210033595A1 (en) 2021-02-04
JP2021501318A (ja) 2021-01-14
US20240264151A1 (en) 2024-08-08
WO2019084493A1 (en) 2019-05-02
US11906511B2 (en) 2024-02-20

Similar Documents

Publication Publication Date Title
JP7430136B2 (ja) 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物
JP2023159353A (ja) Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定
US20210172020A1 (en) Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP3347039B1 (en) "immune checkpoint intervention" in cancer
EP3606518A1 (en) Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3695408A1 (en) Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
JP2023500054A (ja) 腫瘍微小環境の分類
US20240158837A1 (en) Epigenetic analysis of cell therapy and related methods
Blum et al. Immune responses in checkpoint myocarditis across heart, blood and tumour
JP7150280B2 (ja) がん免疫療法の新規バイオマーカ
JP2018505658A (ja) Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
CN113710274A (zh) 用于预测癌症免疫疗法中的长期存活的方法及组合物
CN109081866B (zh) 癌症中的t细胞亚群及其特征基因
US20240302349A1 (en) Methods of assessing or monitoring a response to a cell therapy
EP4326319A1 (en) Personalized allogeneic immunotherapy
EP4291897A1 (en) New method to pronostic lung cancer
Köse Understanding Disease Progression and Target Identification for Multiple Myeloma
Singh Characterization of tumor-infiltrating B cells in solid tumors
Bacchiarri Comprehensive Evaluation of PD-L1, BCL-2 by Next-Generation Flow Analysis and FISH Abnormalities of Aberrant Plasma Cells in Patients Affected by Smoldering Multiple Myeloma
JP2024505056A (ja) ポジオチニブを用いてがんを処置する方法
Duhen et al. Providence St. Joseph Health Digital Commons

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240130

R150 Certificate of patent or registration of utility model

Ref document number: 7430136

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150